X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10137) 10137
Book Chapter (127) 127
Magazine Article (10) 10
Dissertation (5) 5
Web Resource (4) 4
Book / eBook (2) 2
Conference Proceeding (2) 2
Government Document (1) 1
Newsletter (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bevacizumab (8986) 8986
humans (8865) 8865
science & technology (7958) 7958
life sciences & biomedicine (7720) 7720
female (5110) 5110
male (4279) 4279
oncology (4054) 4054
angiogenesis inhibitors - therapeutic use (3987) 3987
middle aged (3730) 3730
aged (3421) 3421
antibodies, monoclonal, humanized (2929) 2929
antineoplastic combined chemotherapy protocols - therapeutic use (2850) 2850
adult (2518) 2518
treatment outcome (2489) 2489
vascular endothelial growth factor a - antagonists & inhibitors (2368) 2368
antibodies, monoclonal - therapeutic use (2245) 2245
ophthalmology (2089) 2089
vascular endothelial growth factor (1896) 1896
cancer (1880) 1880
antibodies, monoclonal, humanized - therapeutic use (1837) 1837
chemotherapy (1820) 1820
aged, 80 and over (1495) 1495
care and treatment (1452) 1452
bevacizumab - therapeutic use (1417) 1417
retrospective studies (1413) 1413
antibodies, monoclonal, humanized - administration & dosage (1327) 1327
colorectal neoplasms - drug therapy (1290) 1290
angiogenesis inhibitors - administration & dosage (1198) 1198
antineoplastic agents - therapeutic use (1187) 1187
intravitreal injections (1164) 1164
antibodies, monoclonal - administration & dosage (1139) 1139
metastasis (1124) 1124
colorectal cancer (1111) 1111
angiogenesis (1092) 1092
medicine & public health (1083) 1083
angiogenesis inhibitors (1068) 1068
animals (1024) 1024
disease-free survival (1007) 1007
angiogenesis inhibitors - adverse effects (947) 947
research (923) 923
drug therapy (917) 917
bevacizumab - administration & dosage (914) 914
colorectal neoplasms - pathology (904) 904
prognosis (864) 864
pharmacology & pharmacy (849) 849
tomography, optical coherence (841) 841
antineoplastic combined chemotherapy protocols - adverse effects (839) 839
follow-up studies (832) 832
clinical trials (807) 807
lung neoplasms - drug therapy (793) 793
patients (788) 788
ranibizumab (770) 770
antineoplastic agents (714) 714
analysis (701) 701
fluorouracil - administration & dosage (700) 700
antibodies, monoclonal - adverse effects (691) 691
surgery (681) 681
fluorescein angiography (680) 680
neoplasm metastasis (678) 678
tumors (677) 677
antimitotic agents (676) 676
camptothecin - analogs & derivatives (676) 676
hematology, oncology and palliative medicine (666) 666
neoplasm staging (653) 653
combined modality therapy (650) 650
antibodies, monoclonal, humanized - adverse effects (645) 645
prospective studies (641) 641
brain neoplasms - drug therapy (635) 635
cetuximab (629) 629
cancer therapies (622) 622
health aspects (609) 609
visual acuity - physiology (604) 604
eye diseases (599) 599
carcinoma, non-small-cell lung - drug therapy (597) 597
abridged index medicus (594) 594
survival rate (585) 585
macular degeneration (578) 578
breast neoplasms - drug therapy (576) 576
visual acuity (544) 544
neovascularization, pathologic - drug therapy (535) 535
vegf (529) 529
antineoplastic combined chemotherapy protocols - administration & dosage (527) 527
organoplatinum compounds - administration & dosage (523) 523
young adult (514) 514
macular edema - drug therapy (501) 501
breast cancer (496) 496
choroidal neovascularization - drug therapy (493) 493
deoxycytidine - analogs & derivatives (490) 490
camptothecin - administration & dosage (489) 489
clinical trials as topic (480) 480
genetic structures (478) 478
vascular endothelial growth factor a - metabolism (475) 475
randomized controlled trials as topic (464) 464
survival (462) 462
survival analysis (461) 461
monoclonal antibodies (456) 456
disease progression (450) 450
macular degeneration - drug therapy (447) 447
glioblastoma - drug therapy (446) 446
neurosciences & neurology (446) 446
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9715) 9715
Japanese (290) 290
French (164) 164
German (118) 118
Spanish (67) 67
Chinese (57) 57
Portuguese (34) 34
Hungarian (25) 25
Czech (16) 16
Italian (15) 15
Russian (15) 15
Romanian (11) 11
Polish (9) 9
Korean (8) 8
Dutch (7) 7
Finnish (5) 5
Norwegian (5) 5
Hebrew (2) 2
Slovak (2) 2
Swedish (2) 2
Turkish (2) 2
Arabic (1) 1
Danish (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 03/2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Index Medicus | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Current medicinal chemistry, ISSN 0929-8673, 02/2008, Volume 15, Issue 5, pp. 422 - 432
Journal Article
Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 07/2014, Volume 12, Issue 7, pp. 1028 - 1059
.... This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care... 
Life Sciences & Biomedicine | Oncology | Science & Technology | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colonic Neoplasms - drug therapy | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Bevacizumab | Colonic Neoplasms - surgery | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Deoxycytidine - adverse effects | Leucovorin - therapeutic use | Cetuximab | Liver Neoplasms - secondary | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Camptothecin - therapeutic use | Fluorouracil - analogs & derivatives | Membrane Proteins - genetics | Liver Neoplasms - drug therapy | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects
Journal Article
Journal of cancer research and clinical oncology, ISSN 0171-5216, 5/2015, Volume 141, Issue 5, pp. 909 - 921
Vascular endothelial growth factor signaling pathway plays a crucial role in angiogenesis and has become a promising target for cancer drug development. We... 
Angiogenesis | Medicine & Public Health | Hematology | Antibody | Tyrosine kinase inhibitor | Non-small cell lung cancer | Oncology | Cancer Research | Internal Medicine | Life Sciences & Biomedicine | Science & Technology | Niacinamide - analogs & derivatives | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Receptors, Vascular Endothelial Growth Factor - metabolism | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Odds Ratio | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Non-Small-Cell Lung - metabolism | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Thrombocytopenia - chemically induced | Randomized Controlled Trials as Topic | Disease-Free Survival | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Indoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Hemorrhage - chemically induced | Lung cancer, Small cell | Development and progression | Angiogenesis inhibitors | Lung cancer, Non-small cell | Analysis | Index Medicus
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 11/2016, Volume 50, pp. 109 - 117
... are approved for first-line or later-line use in the treatment of patients with mRCC [1–3] . Among these agents, 1 is a monoclonal antibody targeting vascular endothelial... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer | Index Medicus
Journal Article